187 related articles for article (PubMed ID: 20723544)
1. Interval fecal immunochemical testing in a colonoscopic surveillance program speeds detection of colorectal neoplasia.
Lane JM; Chow E; Young GP; Good N; Smith A; Bull J; Sandford J; Morcom J; Bampton PA; Cole SR
Gastroenterology; 2010 Dec; 139(6):1918-26. PubMed ID: 20723544
[TBL] [Abstract][Full Text] [Related]
2. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
Smith A; Young GP; Cole SR; Bampton P
Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
[TBL] [Abstract][Full Text] [Related]
3. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon.
Lieberman DA; Weiss DG;
N Engl J Med; 2001 Aug; 345(8):555-60. PubMed ID: 11529208
[TBL] [Abstract][Full Text] [Related]
4. Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer?
Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Niv Y
Aliment Pharmacol Ther; 2006 Nov; 24(10):1475-81. PubMed ID: 17032281
[TBL] [Abstract][Full Text] [Related]
5. Interval fecal immunochemical testing in colonoscopic surveillance program.
Lieberman D; Imperiale TF
Gastroenterology; 2011 Apr; 140(4):1359-60; author reply 1360-1. PubMed ID: 21354170
[No Abstract] [Full Text] [Related]
6. A quantitative immunochemical fecal occult blood test for colorectal neoplasia.
Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Leshno M; Niv Y
Ann Intern Med; 2007 Feb; 146(4):244-55. PubMed ID: 17310048
[TBL] [Abstract][Full Text] [Related]
7. Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology.
Bampton PA; Sandford JJ; Cole SR; Smith A; Morcom J; Cadd B; Young GP
Gut; 2005 Jun; 54(6):803-6. PubMed ID: 15888788
[TBL] [Abstract][Full Text] [Related]
8. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests.
Haug U; Hundt S; Brenner H
Am J Gastroenterol; 2010 Mar; 105(3):682-90. PubMed ID: 19953091
[TBL] [Abstract][Full Text] [Related]
9. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test.
Vilkin A; Rozen P; Levi Z; Waked A; Maoz E; Birkenfeld S; Niv Y
Am J Gastroenterol; 2005 Nov; 100(11):2519-25. PubMed ID: 16279909
[TBL] [Abstract][Full Text] [Related]
10. Higher fecal immunochemical test cutoff levels: lower positivity rates but still acceptable detection rates for early-stage colorectal cancers.
Terhaar sive Droste JS; Oort FA; van der Hulst RW; van Heukelem HA; Loffeld RJ; van Turenhout ST; Ben Larbi I; Kanis SL; Neerincx M; Räkers M; Coupé VM; Bouman AA; Meijer GA; Mulder CJ
Cancer Epidemiol Biomarkers Prev; 2011 Feb; 20(2):272-80. PubMed ID: 21135261
[TBL] [Abstract][Full Text] [Related]
11. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening.
Park DI; Ryu S; Kim YH; Lee SH; Lee CK; Eun CS; Han DS
Am J Gastroenterol; 2010 Sep; 105(9):2017-25. PubMed ID: 20502450
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population.
Morikawa T; Kato J; Yamaji Y; Wada R; Mitsushima T; Shiratori Y
Gastroenterology; 2005 Aug; 129(2):422-8. PubMed ID: 16083699
[TBL] [Abstract][Full Text] [Related]
13. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
[TBL] [Abstract][Full Text] [Related]
14. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
Quintero E
Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
[TBL] [Abstract][Full Text] [Related]
15. Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed.
Rozen P; Levi Z; Hazazi R; Waked A; Vilkin A; Maoz E; Birkenfeld S; Leshno M; Niv Y
Aliment Pharmacol Ther; 2009 Apr; 29(8):906-17. PubMed ID: 19183147
[TBL] [Abstract][Full Text] [Related]
16. Comparative screening with a sensitive guaiac and specific immunochemical occult blood test in an endoscopic study.
Rozen P; Knaani J; Samuel Z
Cancer; 2000 Jul; 89(1):46-52. PubMed ID: 10896999
[TBL] [Abstract][Full Text] [Related]
17. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia.
Limburg PJ; Devens ME; Harrington JJ; Diehl NN; Mahoney DW; Ahlquist DA
Am J Gastroenterol; 2003 Oct; 98(10):2299-305. PubMed ID: 14572583
[TBL] [Abstract][Full Text] [Related]
18. New stool screening tests for colorectal cancer.
Young GP; Cole S
Digestion; 2007; 76(1):26-33. PubMed ID: 17947816
[TBL] [Abstract][Full Text] [Related]
19. Colonoscopy: a review of its yield for cancers and adenomas by indication.
Rex DK
Am J Gastroenterol; 1995 Mar; 90(3):353-65. PubMed ID: 7872270
[TBL] [Abstract][Full Text] [Related]
20. A prospective study of a new immunochemical fecal occult blood test in Korean patients referred for colonoscopy.
Woo HY; Mok RS; Park YN; Park DI; Sung IK; Sohn CI; Park H
Clin Biochem; 2005 Apr; 38(4):395-9. PubMed ID: 15766742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
